FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Dexamethasone, Tobramycin Suspension/ Drops
Status: Discontinuation
»Therapeutic Categories: Ophthalmology

Expand all

Novartis Pharmaceuticals Corporation (New 06/26/2023)

Company Contact Information:
888-669-6682

Presentation	Posting Date	Related Information
Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-40)	06/26/2023	Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns. Product will be available until approximately September 2023. The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz. Other generic equivalents are also available.
Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-25)	06/26/2023	Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns. Product will be available until approximately September 2023. The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz. Other generic equivalents are also available.
Tobradex, Suspension/ Drops, 1 mg/1 mL; 3 mg/1 mL (NDC 0078-0953-26)	06/26/2023	Novartis Pharmaceuticals has made a business decision to permanently discontinue TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension) Sterile suspension. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns. Product will be available until approximately September 2023. The authorized generic, 2.5 mL NDC 61314-647-25, 5 mL NDC 61314-647-05 and 10 mL NDC 61314-647-10 will continue to be manufactured and available, distributed by Sandoz. Other generic equivalents are also available.